Status:
WITHDRAWN
A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects
Lead Sponsor:
Pfizer
Conditions:
Obesity
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This study examines whether a gradual increase of dose improves the gastrointestinal tolerability (nausea and vomiting) of PF05212389
Eligibility Criteria
Inclusion
- Obesity
Exclusion
- Diabetes mellitus (type 1 or type 2) Heart failure Eating disorders Psychiatric disorders History of suicide attempt History of pancreatitis
Key Trial Info
Start Date :
April 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01472848
Start Date
April 1 2011
End Date
August 1 2011
Last Update
November 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.